Quick Answer
MANGOCEUTICALS, INC. reported Diluted EPS of $4.84 per share (loss) for fiscal year 2024.
MANGOCEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$4.84 | +43.6% |
| 2023 | -$8.58 | -4415.8% |
| 2022 | -$0.19 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.69 | +39.5% | -21.1% |
| June 30, 2025 | -$0.57 | +58.4% | +55.8% |
| March 31, 2025 | -$1.29 | +14.0% | -13.2% |
| September 30, 2024 | -$1.14 | +32.9% | +16.8% |
| June 30, 2024 | -$1.37 | -878.6% | +8.7% |
| March 31, 2024 | -$1.50 | -552.2% | +11.8% |
| September 30, 2023 | -$1.70 | -1600.0% | -1114.3% |
| June 30, 2023 | -$0.14 | -250.0% | +39.1% |
- MANGOCEUTICALS, INC. showed an increase of +43.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2024 period, MANGOCEUTICALS, INC.’s diluted eps has declined by 2447.4% (from $0.19 per share (loss) to $4.84 per share (loss)).
- The most recent figure is from MANGOCEUTICALS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 20, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: